Pharmaceutical

With FDA greenlight, BMS Breyanzi brings CAR-T cell therapy to CLL and SLL

Amidst the many BTK inhibitors, Breyanzi will be the first and only CAR-T cell therapy available for the treatment of CLL and SLL.

Mar 16, 2024 - 00:00
With FDA greenlight, BMS Breyanzi brings CAR-T cell therapy to CLL and SLL
Amidst the many BTK inhibitors, Breyanzi will be the first and only CAR-T cell therapy available for the treatment of CLL and SLL.
Read the original article

Tags:

Previous Article

BeiGene spin-out Pi Health raises $30m to uptick cancer trial enrolment

Next Article

FDA committee back Geron’s blood disorder drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Magenta Therapeutics and Dianthus agree to merge operations

Magenta Therapeutics and Dianthus agree to merge operat...

May 4, 2023

STAT+: A new mom’s illness led to the first diagnosis of a rare condition after childbirth

STAT+: A new mom’s illness led to the first diagnosis o...

Aug 17, 2023

Mustang Bio’s MB-108 receives FDA orphan drug status for glioma treatment

Mustang Bio’s MB-108 receives FDA orphan drug status fo...

Nov 9, 2024